Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsHye Won Lee, Hungta Chen, Filip Surmont et al.|Journal of the American College of Cardiology|2018Cited by 465
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery DiseaseMasato Nakamura, Atsushi Hirayama, Kazuo Kimura et al.|Circulation Journal|2020Cited by 345
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Matthias Saathoff, Dianna J. Magliano et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93
Study Profile of the Tsuruoka Metabolomics Cohort Study (TMCS)Sei Harada, S. Koshiba, Miho Iida et al.|Journal of Epidemiology|2024Cited by 7